Drug:
Reaction: ACCIDENTAL EXPOSURE TO PRODUCT
20250101 - 20251231
No. 401 - 500
| No. | safetyreportid |
occurcountry |
patientonsetage |
patientsex 1:M 2:F |
|---|---|---|---|---|
Adverse reaction |
||||
Drug (openfda.generic_name, medicinalproduct) |
||||
| 401 | 25081315 |
US |
1 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 402 | 25081325 |
US |
32 | 2 |
Injection site bruising, Accidental exposure to product, Exposure via skin contact, Device use issue, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 403 | 25081366 |
US |
39 | 2 |
Exposure via skin contact, Wrong technique in device usage process, Accidental exposure to product, |
||||
BELIMUMAB, |
||||
| 404 | 25081488 |
US |
79 | 2 |
Injection site pain, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, MONTELUKAST, ALBUTEROL SULFATE, ARFORMOTEROL TARTRATE, BUDESONIDE, VIBEGRON, LEVOTHYROXINE, REVEFENACIN, CETIRIZINE HYDROCHLORIDE, |
||||
| 405 | 25081495 |
PE |
39 | 1 |
Needle issue, Accidental exposure to product, |
||||
GUSELKUMAB, GUSELKUMAB, |
||||
| 406 | 25081512 |
US |
43 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 407 | 25081591 |
US |
72 | 2 |
Anxiety, Insomnia, Nervousness, Pruritus, Rash macular, Accidental exposure to product, Device use error, Device difficult to use, Agitation, Sinus disorder, |
||||
EVOLOCUMAB, EVOLOCUMAB, |
||||
| 408 | 25081611 |
US |
62 | 2 |
Injection site pain, Headache, Dyskinesia, Incorrect dose administered by device, Device use error, Accidental exposure to product, |
||||
EVOLOCUMAB, |
||||
| 409 | 25080487 |
US |
42 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 410 | 25080502 |
US |
||
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 411 | 25080508 |
US |
86 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 412 | 25080509 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 413 | 25080522 |
US |
66 | 2 |
Device difficult to use, Accidental exposure to product, Drug dose omission by device, Injection site haemorrhage, |
||||
EVOLOCUMAB, EVOLOCUMAB, EVOLOCUMAB, |
||||
| 414 | 25080598 |
US |
83 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 415 | 25080645 |
US |
79 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 416 | 25080671 |
US |
||
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 417 | 25080672 |
US |
42 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, OMEPRAZOLE, OMEPRAZOLE MAGNESIUM, AZELASTINE, |
||||
| 418 | 25080679 |
US |
61 | 2 |
Accidental exposure to product, Exposure via skin contact, Intentional product use issue, |
||||
DUPILUMAB, |
||||
| 419 | 25080802 |
US |
51 | 2 |
Accidental exposure to product, Wrong technique in product usage process, Injury associated with device, Drug dose omission by device, |
||||
ERENUMAB-AOOE, ERENUMAB-AOOE, |
||||
| 420 | 25081006 |
US |
72 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 421 | 25081060 |
US |
27 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 422 | 25077101 |
US |
||
Hypoaesthesia oral, Accidental exposure to product, Wrong technique in product usage process, Paraesthesia oral, |
||||
DICLOFENAC SODIUM, |
||||
| 423 | 25077158 |
US |
2 | |
Accidental exposure to product, Device defective, |
||||
SECUKINUMAB, HYDROXYCHLOROQUINE, DULOXETINE HYDROCHLORIDE, DULOXETINE, ARMODAFINIL, |
||||
| 424 | 25077182 |
US |
64 | 2 |
Impaired quality of life, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, OXYCODONE AND ACETAMINOPHEN, OXYCODONE HYDROCHLORIDE AND ACETAMINOPHEN, OXYCODONE AND ACETAMINOPHEN TABLETS, PREDNISONE, MORPHINE SULFATE, DULAGLUTIDE, BUPROPION HYDROCHLORIDE, LIDOCAINE, LIDOCAINE HYDROCHLORIDE, BURN RELIEF, MAXIMUM STRENGTH PAIN RELIEVER, LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE, LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE, LIDOCAINE 4%, LIDOCAINE, MENTHOL, OMEPRAZOLE, OMEPRAZOLE MAGNESIUM, LOSARTAN POTASSIUM, LOSARTAN, FLUTICASONE FUROATE AND VILANTEROL TRIFENATATE, SIMVASTATIN, AZELASTINE, TERIPARATIDE, CARISOPRODOL, ETANERCEPT, ALPRAZOLAM, PREGABALIN, METFORMIN, METFORMIN ER 500 MG, METFORMIN ER 750 MG, BACLOFEN, INSULIN GLARGINE, |
||||
| 425 | 25077188 |
US |
3 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, DUPILUMAB, CETIRIZINE HYDROCHLORIDE, |
||||
| 426 | 25077265 |
US |
||
Treatment delayed, Accidental exposure to product, Wrong technique in product usage process, Wrong technique in product usage process, |
||||
TENECTEPLASE, |
||||
| 427 | 25077338 |
US |
74 | 1 |
Injection site indentation, Product communication issue, Product preparation error, Device difficult to use, Accidental exposure to product, Wrong technique in product usage process, |
||||
EVOLOCUMAB, EVOLOCUMAB, SEMAGLUTIDE, |
||||
| 428 | 25077363 |
US |
||
Adverse event, Device malfunction, Exposure via skin contact, Accidental exposure to product, |
||||
INFLIXIMAB-DYYB, |
||||
| 429 | 25077389 |
US |
||
Device use error, Accidental exposure to product, Exposure via skin contact, |
||||
INFLIXIMAB-DYYB, MONTELUKAST SODIUM, CETIRIZINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE, ERGOCALCIFEROL, METFORMIN, METFORMIN ER 500 MG, METFORMIN ER 750 MG, FLUTICASONE PROPIONATE, TRIPROLIDINE HCL, ACETAMINOPHEN, CHLORPHENIRAMINE MALEATE, PHENYLEPHRINE HCL, |
||||
| 430 | 25077583 |
US |
22 | |
Injection site pain, Accidental exposure to product, Device difficult to use, Drug dose omission by device, Wrong technique in product usage process, |
||||
ERENUMAB-AOOE, |
||||
| 431 | 25077584 |
US |
77 | |
Accidental exposure to product, Therapy interrupted, Product communication issue, |
||||
EVOLOCUMAB, EVOLOCUMAB, |
||||
| 432 | 25077663 |
US |
||
Accidental exposure to product, Exposure via skin contact, Device breakage, |
||||
INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, |
||||
| 433 | 25077976 |
US |
38 | 2 |
Cough, Asthma, Injection site pain, COVID-19, Sneezing, Injection site haemorrhage, Accidental exposure to product, Device difficult to use, Drug dose omission by device, Device use error, |
||||
ERENUMAB-AOOE, |
||||
| 434 | 25078040 |
US |
57 | 1 |
Exposure via skin contact, Injection site haemorrhage, Somnolence, Fatigue, Wrong technique in device usage process, Accidental exposure to product, Product complaint, |
||||
BELIMUMAB, BELIMUMAB, |
||||
| 435 | 25078139 |
US |
56 | 1 |
Peripheral swelling, Headache, Accidental exposure to product, Needle issue, Device defective, Underdose, |
||||
OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, LEVOTHYROXINE, FINASTERIDE, BUPROPION HYDROCHLORIDE, SEMAGLUTIDE, ONABOTULINUMTOXINA, |
||||
| 436 | 25078580 |
US |
2 | |
Device issue, Accidental exposure to product, Drug dose omission by device, Device leakage, |
||||
SECUKINUMAB, CLINDAMYCIN PHOSPHATE, CLINDAMYCIN, |
||||
| 437 | 25078587 |
US |
||
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 438 | 25078601 |
US |
||
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 439 | 25079043 |
US |
30 | 2 |
Accidental exposure to product, Device deployment issue, Product dose omission issue, |
||||
GUSELKUMAB, GUSELKUMAB, |
||||
| 440 | 25079069 |
US |
66 | 2 |
Device difficult to use, Drug dose omission by device, Product communication issue, Product dispensing issue, Accidental exposure to product, Injection site pain, Wrong technique in product usage process, |
||||
EVOLOCUMAB, EVOLOCUMAB, |
||||
| 441 | 25079184 |
US |
65 | 1 |
Injection site haemorrhage, Device difficult to use, Accidental exposure to product, |
||||
EVOLOCUMAB, |
||||
| 442 | 25079286 |
US |
2 | |
Device malfunction, Accidental exposure to product, Exposure via skin contact, Device leakage, Drug dose omission by device, |
||||
SECUKINUMAB, |
||||
| 443 | 25079380 |
US |
18 | 2 |
Contusion, Device malfunction, Accidental exposure to product, Device issue, Needle issue, Burning sensation, |
||||
FREMANEZUMAB-VFRM, |
||||
| 444 | 25079690 |
HU |
||
Device deployment issue, Accidental exposure to product, |
||||
GOLIMUMAB, |
||||
| 445 | 25079745 |
US |
84 | 2 |
Ventricular extrasystoles, Device difficult to use, Wrong technique in product usage process, Accidental exposure to product, Drug dose omission by device, |
||||
ERENUMAB-AOOE, |
||||
| 446 | 25079754 |
US |
28 | 2 |
Product complaint, Accidental exposure to product, Pruritus, Swelling face, |
||||
OMALIZUMAB, |
||||
| 447 | 25079840 |
US |
16 | 2 |
Exposure via skin contact, Accidental exposure to product, |
||||
DUPILUMAB, |
||||
| 448 | 25080079 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, DUPILUMAB, GUAIFENESIN, ALBUTEROL SULFATE, FLUTICASONE FUROATE, UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE, ALBUTEROL SULFATE, |
||||
| 449 | 25080279 |
US |
2 | |
Device difficult to use, Accidental exposure to product, Injection site reaction, Drug dose omission by device, |
||||
ERENUMAB-AOOE, |
||||
| 450 | 25071679 |
US |
71 | 1 |
Injection site pain, Accidental exposure to product, Device difficult to use, Injection site injury, Injection site haemorrhage, Drug dose omission by device, |
||||
EVOLOCUMAB, |
||||
| 451 | 25071746 |
US |
2 | |
Accidental exposure to product, Product dose omission issue, |
||||
SECUKINUMAB, |
||||
| 452 | 25071817 |
US |
2 | |
Injury associated with device, Accidental exposure to product, Exposure via skin contact, |
||||
INSULIN GLARGINE, |
||||
| 453 | 25071842 |
US |
1 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 454 | 25071894 |
US |
69 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 455 | 25071989 |
US |
61 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 456 | 25072012 |
US |
44 | 2 |
Injection site pain, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 457 | 25072051 |
US |
2 | |
Extra dose administered, Device difficult to use, Accidental exposure to product, |
||||
BRIMONIDINE TARTRATE, |
||||
| 458 | 25072097 |
US |
55 | 2 |
Accidental exposure to product, Exposure via skin contact, Off label use, |
||||
DUPILUMAB, DUPILUMAB, DUPILUMAB, |
||||
| 459 | 25072125 |
US |
36 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 460 | 25072137 |
US |
2 | |
Wrong technique in product usage process, No adverse event, Accidental exposure to product, |
||||
TOCILIZUMAB, TOCILIZUMAB, |
||||
| 461 | 25072139 |
US |
50 | 2 |
Accidental exposure to product, Off label use, No adverse event, |
||||
TOCILIZUMAB, TOCILIZUMAB, METHOTREXATE, METHOTREXATE SODIUM, FOLIC ACID, |
||||
| 462 | 25072273 |
US |
65 | 1 |
Product dose omission issue, Accidental exposure to product, Wrong technique in device usage process, Drug ineffective, Device malfunction, Syringe issue, Pruritus, Urticaria, |
||||
OMALIZUMAB, OMALIZUMAB, ALPRAZOLAM, OMEPRAZOLE MAGNESIUM, OMEPRAZOLE MAGNESIUM, CETIRIZINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE, MONTELUKAST, DIPHENHYDRAMINE HYDROCHLORIDE, |
||||
| 463 | 25072297 |
US |
68 | 1 |
Exposure via skin contact, Incorrect dose administered, Accidental exposure to product, Product complaint, |
||||
MEPOLIZUMAB, |
||||
| 464 | 25072356 |
US |
2 | |
Injury associated with device, Accidental exposure to product, Occupational exposure to product, |
||||
| 465 | 25072924 |
US |
39 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 466 | 25072926 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 467 | 25072943 |
US |
32 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 468 | 25073094 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 469 | 25073095 |
US |
69 | 2 |
Injection site pain, Eye irritation, Incorrect dose administered, Exposure via eye contact, Accidental exposure to product, |
||||
DUPILUMAB, |
||||
| 470 | 25073164 |
US |
51 | 2 |
Accidental exposure to product, Device difficult to use, Drug ineffective, Drug dose omission by device, |
||||
ERENUMAB-AOOE, ERENUMAB-AOOE, |
||||
| 471 | 25073204 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 472 | 25073286 |
US |
68 | 1 |
Accidental exposure to product, Exposure via mucosa, |
||||
DUPILUMAB, |
||||
| 473 | 25074298 |
US |
2 | |
Device leakage, Accidental exposure to product, Incorrect dose administered by device, Product dose omission issue, |
||||
SECUKINUMAB, |
||||
| 474 | 25074433 |
US |
2 | |
Accidental exposure to product, |
||||
IBUPROFEN, |
||||
| 475 | 25074689 |
US |
40 | 2 |
Exposure via skin contact, Wrong technique in device usage process, Accidental exposure to product, |
||||
BELIMUMAB, HYDROXYCHLOROQUINE, LEVETIRACETAM, SILDENAFIL CITRATE, SILDENAFIL, SILDENAFIL POWDER,, IRON, VITAMIN C, LANSOPRAZOLE, LIDOCAINE, LIDOCAINE HYDROCHLORIDE, BURN RELIEF, MAXIMUM STRENGTH PAIN RELIEVER, LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE, LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE, LIDOCAINE 4%, LIDOCAINE, MENTHOL, |
||||
| 476 | 25075782 |
US |
66 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 477 | 25075861 |
US |
||
Accidental exposure to product, Vision blurred, Abnormal sensation in eye, |
||||
RUXOLITINIB, |
||||
| 478 | 25075960 |
US |
67 | 2 |
Device use error, Accidental exposure to product, Injection site pain, |
||||
EVOLOCUMAB, EVOLOCUMAB, |
||||
| 479 | 25076512 |
US |
62 | 2 |
Exposure via skin contact, Injection site pain, Wrong technique in device usage process, Accidental exposure to product, Accidental underdose, Product complaint, |
||||
BELIMUMAB, |
||||
| 480 | 25076747 |
US |
1 | |
Accidental exposure to product, |
||||
GALCANEZUMAB-GNLM, |
||||
| 481 | 25076832 |
US |
59 | 2 |
Device difficult to use, Accidental exposure to product, Wrong technique in product usage process, Drug dose omission by device, Injection site bruising, Injection site pain, Injection site haemorrhage, |
||||
EVOLOCUMAB, |
||||
| 482 | 25066144 |
US |
||
Device malfunction, Hypoaesthesia, Headache, Exposure via skin contact, Accidental exposure to product, |
||||
INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, DICYCLOMINE HYDROCHLORIDE, ERGOCALCIFEROL, CYANOCOBALAMIN, OMEPRAZOLE, OMEPRAZOLE MAGNESIUM, |
||||
| 483 | 25066244 |
US |
60 | 1 |
Device use error, Product dose omission issue, Accidental exposure to product, |
||||
USTEKINUMAB, USTEKINUMAB, |
||||
| 484 | 25066352 |
US |
2 | |
Exposure via skin contact, Accidental exposure to product, |
||||
FLUTICASONE FUROATE, UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE, |
||||
| 485 | 25066481 |
US |
||
Accidental exposure to product, Exposure via skin contact, Wrong technique in product usage process, |
||||
INFLIXIMAB-DYYB, |
||||
| 486 | 25066492 |
US |
2 | |
Accidental exposure to product, Failure of child resistant product closure, |
||||
CETIRIZINE HYDROCHLORIDE, |
||||
| 487 | 25066586 |
US |
2 | |
Device difficult to use, Device leakage, Accidental exposure to product, Inappropriate schedule of product administration, |
||||
SECUKINUMAB, |
||||
| 488 | 25066616 |
US |
||
Drug delivery system malfunction, Accidental exposure to product, Exposure via skin contact, Wrong technique in product usage process, |
||||
INFLIXIMAB-DYYB, ESCITALOPRAM, |
||||
| 489 | 25066653 |
US |
||
Wrong technique in product usage process, Exposure via skin contact, Accidental exposure to product, Drug dose omission by device, Intentional product use issue, |
||||
INFLIXIMAB-DYYB, |
||||
| 490 | 25066685 |
US |
1 | |
Exposure via skin contact, Accidental exposure to product, Product complaint, |
||||
MEPOLIZUMAB, ROSUVASTATIN, LISINOPRIL, |
||||
| 491 | 25066723 |
US |
2 | |
Accidental exposure to product, Product dose omission issue, Device issue, |
||||
SECUKINUMAB, |
||||
| 492 | 25067101 |
US |
27 | 1 |
Needle issue, Product use complaint, Device leakage, Accidental exposure to product, Drug dose omission by device, |
||||
SECUKINUMAB, |
||||
| 493 | 25067103 |
US |
2 | |
Cataract operation, Circumstance or information capable of leading to medication error, Product use complaint, Accidental exposure to product, Exposure via skin contact, |
||||
GLYCERIN, |
||||
| 494 | 25067429 |
US |
39 | 2 |
Injection site pain, Injection site reaction, Accidental exposure to product, Incorrect dose administered by device, Wrong technique in product usage process, |
||||
ERENUMAB-AOOE, |
||||
| 495 | 25067498 |
US |
2 | |
Device issue, Device leakage, Accidental exposure to product, |
||||
SECUKINUMAB, ROMOSOZUMAB-AQQG, |
||||
| 496 | 25067869 |
US |
69 | 1 |
Exposure via skin contact, Wrong technique in device usage process, Accidental exposure to product, |
||||
FLUTICASONE FUROATE, UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE, OXYGEN, 0XYGEN, |
||||
| 497 | 25068303 |
US |
34 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 498 | 25068312 |
US |
1 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 499 | 25068321 |
US |
77 | 2 |
Oral herpes, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, PANTOPRAZOLE, ROSUVASTATIN, FLUOXETINE HYDROCHLORIDE, FLUOXETINE, MONTELUKAST, CETIRIZINE, CETIRIZINE HYDROCHLORIDE, CETIIRIZINE, TIOTROPIUM BROMIDE, |
||||
| 500 | 25068364 |
US |
||
Rebound eczema, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
disclaimer
Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.
terms
license
last_updated
2025-04-28